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Abstract: Colorectal cancer is one of the most common types of cancer. Drug resistance and drug-induced damage of healthy tissues
are major obstacles in cancer treatment. Therefore, to develop efficient anticancer therapy, it is necessary to find compounds that affect
tumor cells, but do not exhibit toxicity to healthy cells. Caffeic acid phenethyl ester (CAPE) has been demonstrated to have anticancer
properties in many types of cancer. In this study, the cytotoxic and apoptotic effects of CAPE on the RKO colorectal cancer cell line and
CCD 841-CoN normal colorectal cell line was investigated. In addition, changes in the survivin expression were determined. According to the results, CAPE decreased cell viability in the RKO cell line in a dose-dependent manner. Likewise, CAPE induced apoptotic
cell death in approximately 40% of the RKO cells. Furthermore, CAPE treatment increased the Serine 15 (Ser15) and Serine 46 (Ser46)
phosphorylation of p53, while decreased the survivin expression. The results suggested that CAPE induced apoptosis by regulating p53
phosphorylation, leading to inhibition of the survivin expression. In accordance with the results, it is suggested that CAPE might be
evaluated as an alternative drug in cancer therapy and further investigation is needed within this scope.
Key words: Anticarcinogenic agents, apoptosis, caffeic acids, colorectal cancer

1. Introduction
Cancer is a heterogeneous group of diseases characterized
by excessive cell proliferation or the disruption of apoptosis
due to a loss of balance between cell division and cell
death (Wong, 2011). Recently, cancer has been reported
to be the second cause of death worldwide, following
cardiovascular diseases (Global Burden of Disease Cancer
et al. 2019). Among the different types of cancer, colorectal
cancer is one of the most diagnosed and usually develops
due to genetic and environmental factors (Kuipers et
al. 2015). Over the last few years, many important roles
in the molecular mechanism of colorectal cancer have
been identified. However, these improvements have not
fully contributed to diagnosis and treatment (Koehler et
al., 2014). Although standard treatment methods, such
as surgery, chemotherapy, and radiotherapy, have been
used clinically, side effects of the chemotherapeutics and
resistance to drugs are important problems that still have
not been overcome (Urruticoechea et al., 2010). Therefore,
alternative treatment strategies with high efficacy and few
side effects are needed. In this context, various natural
compounds that exhibit antiproliferative effects, by

regulating apoptosis, are considered to be potential drug
candidates in cancer therapy (Fulda, 2010).
Caffeic acid phenethyl ester (CAPE) is the main
active phenolic compound of honeybee propolis. CAPE
possesses different characteristics, such as antimicrobial,
antiviral, antioxidant, and anticancer properties (Dos
Santos and Monte-Alto-Costa, 2013; Sulaiman et al.,
2014). It is known that CAPE is a candidate for anticancer
drug studies due to its selective cytotoxic effects on cancer
cells (Murtaza et al., 2014). Furthermore, CAPE treatment
has been shown to negatively regulate cell proliferation via
various signaling pathways and induce apoptosis upon the
activation of p53 (Natarajan et al., 2013; Lin et al., 2015).
Survivin, a member of the inhibitor of apoptosis (IAP)
protein family, is known to be a mitotic regulator that
plays an important role in the abnormal proliferation of
cancer cells. It is overexpressed in fetal tissues and many
tumors, but barely present or completely absent in normal
adult tissues. Overexpression of survivin is associated with
decreased survival rate and it has been shown in many
types of cancer, including colorectal cancer (Cheung et
al., 2013). Survivin suppresses apoptosis by inhibiting
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caspases. Therefore, the downregulation of survivin blocks
tumor growth by inducing apoptosis (Mita et al., 2008).
Hence, targeting survivin in cancer treatment is thought
to be a promising method.
p53 is a tumor suppressor gene and its mutations
are frequently seen in tumorigenesis. Activated p53
is involved in different cellular mechanisms such as
DNA repair, cell cycle arrest, and apoptosis (Hafner
et al., 2019). p53 can regulate different physiological
functions by being phosphorylated at multiple sites.
Serine 15 (Ser15) phosphorylation plays the main role
in DNA damage response. This phosphorylation impairs
the interaction between p53 and its negative regulator,
MDM2; hence, providing the dissociation of p53 from
MDM2 and promoting the activation of p53. Ser15
phosphorylation also provokes a series of phosphorylation
of p53, including Serine 46 (Ser46) phosphorylation,
which further contributes to the induction of apoptosis.
Ser46 phosphorylated p53 shows higher affinity to the
promoters of apoptosis-related genes and activates
apoptosis. Therefore, it is known that the phosphorylation
of Ser46 is correlated with the apoptotic activity of p53
(Oda et al., 2000; Loughery et al., 2014).
In the molecular mechanisms of the disruption of
apoptotic balance and the process of carcinogenesis, it
is believed that there is a link between the regulatory
functions of p53 and survivin. In cellular stress conditions,
phosphorylated p53 inhibits antiapoptotic gene targets,
including survivin. Moreover, it has been stated that
survivin regulates p53 expression. p53-mediated apoptotic
response has been shown to decrease via the overexpression
of survivin (Mirza et al., 2002; Chen et al., 2016; Li et al.,
2018). Since survivin suppresses apoptosis by inhibiting
caspases, the downregulation of survivin is thought to be
critical for successful p53-mediated apoptotic response
and hence, cell death.
In the present study, the cytotoxic and apoptotic effects
of CAPE treatment in colorectal cancer cells and normal
colorectal cells was initially determined. After which, the
protein levels of survivin, p53-Ser15, and p53-Ser46 were
analyzed in order to gain insight into the molecular role of
treatment with CAPE. Additionally, the alterations on the
mRNA expression of survivin were verified. To conclude,
the alternative drug potential of CAPE was evaluated in
this study.
2. Materials and methods
2.1. Chemicals and reagents
CAPE, dimethyl sulfoxide (DMSO), acridine orange
(AO), ethidium bromide (EB), and phosphatase inhibitors
(Sigma Aldrich Corp., St. Louis, MO, USA); penicillinstreptomycin, phosphate buffered saline (PBS), fetal
bovine serum (FBS), and McCoy’s 5A (modified) medium

(Gibco, Paisley, UK); L-glutamine and trypsin-EDTA
solution (Biological Industries, Kibbutz Beit Haemek,
Israel); ethanol, beta mercaptoethanol, hydrochloric
acid, methanol, sodium dodecyl sulfate (SDS), sodium
hydroxide, and sodium chloride (Merck, Darmstadt,
Germany); complete mini protease inhibitor (Roche, Basel,
Switzerland); tween 20 (JT Baker, Phillipsburg, NJ, USA);
bovine serum albumin (BSA) (Amresco, Solon, OH, USA);
EMEM media (Lonza.Verviers, BE); ECL Plus western blot
detection kit, antimouse-HRP (170-5047), and antirabbitHRP(170-5045) antibodies (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA); antisurvivin rabbit monoclonal
antibody (ab76424), anti-p53 (phosphoS46) rabbit
monoclonal antibody (ab76242), anti-p53 (phosphoS15)
rabbit polyclonal antibody (ab1431), antiglyceraldehyde
3-phosphate dehydrogenase (GAPDH) mouse monoclonal
antibody (ab125247), and WST-1 cell proliferation reagent
kit (Abcam, Cambridge, MA, USA); RIPA lysis buffer
(Santa Cruz Biotechnology, Inc., Dallas, TX, USA); BCA
protein assay kit (Thermo Fisher Scientific Inc., Waltham,
MA, USA); flow cytometric kits (BD Biosciences, San
Diego, CA, USA); qRT-polymerase chain reaction (PCR)
kits (QIAGEN, Hilden, Germany); and 5-fluorouracil (5FU) (Koçak Pharma, İstanbul, Turkey) were used in this
study.
2.2. Cell culture
The RKO human colorectal carcinoma cell line (from
ATCC, no.CRL-2577) and CCD 841-CoN human normal
colorectal cell line (from ATCC, no.CRL-1790) were
cultured in McCoy’s 5A and EMEM media, respectively.
The media contained L-glutamine (2 µM/mL), 10% heatinactivated FBS, and 1% penicillin and streptomycin. Cells
were seeded in T75 cell culture flasks and incubated at 37
°C in a 5% CO2 humidified incubator. When the culture
reached approximately 80% confluency, cells were removed
from the flasks by trypsinization and passaged. This
procedure was repeated until the end of the experiments.
2.3. Preparation of CAPE and 5-fluorouracil
0.1 g of CAPE was dissolved in 10 mL of DMSO. 5-FU in
the ready-to-use format (0.05 g/mL) was used as a positive
control. Further dilutions of CAPE and 5-FU were made
in the culture media.
2.4. Cell viability
Cells were seeded at a density of 8 × 103 cells per well in
flat-bottomed 96-well cell culture plates and incubated
for 18 h at 37 °C in a 5% CO2 humidified incubator. After
incubation, the culture media was removed from the
wells and the cells were washed with PBS. They were then
treated with different concentrations of CAPE (0–100 µM)
and 5-FU (0–40 µM) for the dose response studies. Culture
media without CAPE or 5-FU were used for the untreated
control group of cells. After treatment, the cells were
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incubated at 37 °C in a 5% CO2 humidified incubator for 72
h. Thereafter, 10 µL of WST-1 dye was added into each well
and the cells were incubated for a further 4 h. Following
the addition of WST-1, the cell viability was measured at a
wavelength of 440 nm using a microplate reader (Versamax
Molecular Devices, Sunnyvale, CA). Upon completion of
the analysis of CAPE or 5-FU alone, the experiments were
repeated using the effective doses of CAPE (75 µM) and
5-FU (10 µM) to perform the cotreatment study. Thus, the
cells were seeded at a density of 8 × 103 cells per well in
96-well cell culture plates and incubated for 18 h at 37 °C
in a 5% CO2 humidified incubator. Following incubation,
the culture media was removed and the cells were washed
with PBS. Next, the cells were treated together with CAPE
and 5-FU, and incubated at 37 °C in a 5% CO2 humidified
incubator for 72 h. At the end of the incubation, the WST1 assay was repeated as indicated.
2.5. Acridine orange/ethidium bromide staining
The cells were seeded at a density of 5 × 104 cells per well in
6-well cell culture plates and incubated for 18 h at 37 °C in
a 5% CO2 humidified incubator. After that, the cells were
treated with 75 µM of CAPE in fresh media and incubated
again at 37 °C in a 5% CO2 humidified incubator for 72
h. Following this incubation, the cells were harvested and
suspended in PBS. A dye mixture of AO/EB that contained
5 µg/µL of AO and 3 µg/µL of EB was prepared. Next, 50 μL
of the dye mixture was mixed gently with 50 µL of the cell
suspension. After which, 20 µL of the mixed sample was
transferred onto glass slides in the dark and covered with
a coverslip. The morphology of the cells was examined
immediately by fluorescence microscopy (Nikon, Minato,
Tokyo, Japan).
2.6. Annexin V/7AAD apoptosis assay
The RKO and CCD 841-CoN cells were seeded in 6-well
plates at a density of 2 × 105 and incubated for 18 h at 37
°C in a 5% CO2 humidified incubator. Next, the cell media
was removed and the cells were treated with 75 µM of
CAPE prior to 72 h of incubation. Afterwards, the cells
were harvested and washed 3 times with PBS. Annexin
V/7AAD staining was performed according to the
manufacturer’s instructions (BD Biosciences, San Diego,
CA, USA; Cat No: 559763). The cells were then analyzed
using a flow cytometer (BD AccuriC6, Becton Dickinson,
East Rutherford, NJ, USA).
2.7. Detection of caspase-3 activation
The cells were seeded in 6-well plates at a density of 2 × 105
and incubated for 18 h at 37 °C in a 5% CO2 humidified
incubator. After that, the cells were treated with 75 µM of
CAPE in fresh media and incubated for 72 h. At the end
of the incubation, the cells were harvested and washed 3
times with PBS. Active caspase-3 detection was performed
using the PE Active Caspase-3 Apoptosis Kit according to
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the manufacturer’s instructions (BD Biosciences; Cat No:
550914). The cells were analyzed on a flow cytometer.
2.8. RNA isolation and real time quantitative PCR (qRTPCR) analysis
Total RNA isolation was performed according to the
instructions of the QIAGEN RNeasy Mini Kit. RNA was
converted to complementary DNA (cDNA) using the
QIAGEN QuantiTect Reverse Transcription Kit following
isolation. The reaction mixture contained reverse
transcriptase, buffer, primer mix, and template RNA.
The PCR reaction was performed at 42 °C for 15 min
and 95 °C for 3 min. Real-time quantitative PCR (qRTPCR) was used to determine the expression level of the
survivin. The forward and reverse primers of survivin
comprised 5′-AGCCCTTTCTCAAGGACCAC-3′ and
5′-CTCTATGGGGTCGTCATCTGG-3′,
respectively.
β-actin was used as the standard control. The
forward and reverse primers of β-actin comprised
and
5′-CTGGCACCACACCTTCTACAATG-3′
5′-CCTGGTAGATGGGCACAGTGTG-3′, respectively.
The reaction was performed at 95 °C for 15 min (preincubation) for 1 cycle; 94 °C for 15 s, 60 °C for 30 s, and
72 °C for 30 s (amplification) for 40 cycles, and 40 °C for
30 s for 1 cycle (cooling) in a Roche Light Cycler 480-II
System (Rotkreuz, Switzerland).
2.9. Western blot
The cells were seeded in 6-well plates at a density of 4 × 105
and incubated for 18 h at 37 °C in a 5% CO2 humidified
incubator. Afterwards, the cells were treated with 75 µM
of CAPE in fresh media and incubated for 72 h. Following
incubation, the cells were washed with ice-cold PBS at 4
°C. After that, 250 µL of RIPA lysis buffer, supplemented
with protease and phosphatase inhibitors, were added to
cells and shaken on an orbital shaker, on ice, for 30 min.
Cell lysates were removed from the 6-well plates using a
cell scraper and centrifuged at 13,000 g for 15 min at 4 °C.
The protein concentration was determined using the BCA
Protein Assay Kit. Equal amounts of protein were loaded
on 12.5% SDS-polyacrylamide gel and electrophoresis was
performed. The proteins were transferred to nitrocellulose
membranes after electrophoresis. The membranes
were blocked for 1 h at room temperature using 2.5%
nonfat dried milk and 2.5% BSA in tris-buffered saline
(TBS). Blotted membranes were incubated with primary
antibodies at 4 °C overnight. The blocking solutions,
comprised antisurvivin rabbit monoclonal antibody
at a dilution of 1/2500, anti-p53 (phosphoS15) rabbit
polyclonal antibody at a dilution of 1/250, anti-p53
(phosphoS46) rabbit monoclonal antibody at a dilution
of 1/1000, and anti-GAPDH mouse monoclonal antibody
at a dilution of 1/5000. Following the primary antibody
incubations, the membranes were washed 3 times with
TBS with tween, containing 0.5% tween 20. Afterwards,
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the membranes were incubated with antimouse-HRP
and antirabbit-HRP secondary antibodies for 1 h at room
temperature. Thereafter, the membranes were developed
in the dark using the ECL Plus Western blotting detection
kit. In the last step, the membranes were visualized and
analyzed using the ChemiDoc MP Imaging system
(BioRad, Hercules, CA, USA).
2.10. Statistical analysis
Statistical data analysis was performed using GraphPad
Prism (Version 8.0; La Jolla, USA). All of the experiments
were repeated at least 3 times with multiple replicates based
on the experiment. Differences between the untreated and
CAPE or 5-FU treatment groups were analyzed using the
student t-test. Differences between the untreated control,
CAPE treatment, 5-FU treatment, and CAPE +5-FU
treatment groups were compared using one-way ANOVA
analysis with the Tukey multiple comparisons test. All of
the data were expressed as the mean ± SD and P < 0.05 was
considered as statistically significant.
3. Results
3.1. Effects of CAPE on the cell viability of the RKO cells
The RKO and CCD 841-CoN cells were treated with
various concentrations of CAPE and 5-FU. Cell viability

was determined using the WST-1 assay. The cytotoxic
effects of 5-FU (2.5–40 µM) increased in a dose-dependent
manner in both cell lines (Figure 1a). CAPE treatment
(5–150 µM) caused an increased cytotoxic effect in the
RKO cells in a dose-dependent manner, while the same
effect was not observed in the normal CCD 841-CoN cells
(Figure 1b). The IC50 values of CAPE were 108 µM in the
RKO cells and 446.5 µM in the CCD 841-CoN cells. The
IC50 values obtained for 5-FU were 23.5 µM in the RKO
cells and 24.2 µM in the CCD 841-CoN cells. The dilutions
of CAPE (75 µM) and 5-FU (10 µM) that killed nearly 40%
of the cells were used to observe whether they would have
any combined effect at the selected doses. Cotreatment of
CAPE with 5-FU caused approximately a 10% increase in
the cytotoxicity of the RKO cells when compared to the
CAPE treatment alone, while a 5% increase was determined
when compared to the 5-FU treatment alone. On the other
hand, the CCD 841-CoN cells were highly affected by the
CAPE +5-FU combination due to the presence of 5-FU
in the combined drug (Figure 2). To clearly observe the
effect of the CAPE treatment at the mRNA and protein
expression levels in subsequent experiments, it was
decided to use a dose of 75 µM of CAPE, which caused
significant cytotoxic activity in the RKO cell line, but was
ineffective in the CCD 841-CoN cell line.

Figure 1. Concentration-dependent change of the RKO and CCD 841-CoN cell viabilities following 5-FU treatment (A) or CAPE
treatment (B). Statistical significance between the negative controls and treated groups was compared using the student t-test. *P < 0.05,
**P < 0.01.
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3.2. Effects of CAPE treatment on apoptotic cell
morphology of the RKO cells
To observe the changes in the cell morphology, the RKO
and CCD 841-CoN cells were treated with 75 µM of CAPE
for 72 h and then stained with AO/EB. It was observed
that AO stained all of the cells, while EB permeated only
the dead or dying cells (Baskićet al., 2006). Therefore, the
green-stained nuclei-containing cells were living cells
that were only stained with AO, while the orange-stained
nuclei-containing cells were apoptotic cells that were
permeable to both AO and EB. According to fluorescence
microscope results, the RKO cells showed apoptotic cell
morphology after the CAPE treatment. No morphological
change was observed in the normal CCD 841-CoN cells
(Figure 3).
3.3. Effects of CAPE treatment on apoptotic cell
population and caspase-3 activation of the RKO cells
The apoptotic cell population and caspase-3 activation
caused by the CAPE treatment in RKO and CCD 841CoN cells were investigated using flow cytometry. A high
proportion of the apoptotic cell population was detected
in the RKO cells that were treated with 75 µM of CAPE for
72 h when compared to the untreated cells (Figures 4a and
4b). In the CCD 841-CoN cells, there was no change in the
apoptotic cell population following the CAPE treatment
(Figures 4c–4e). For the caspase-3 activity analysis, data
from the untreated cells were considered as basal caspase
activity. It was found that the caspase-3 activity increased
by approximately 45% in the RKO cells and 8% in the CCD
841-CoN cells after the CAPE treatment (Figure 5).
3.4. Survivin gene expression following CAPE treatment
qRT-PCR was performed to examine changes in the
survivin gene expression in the RKO and CCD 841-CoN
cell lines. CAPE treatment of the RKO cells resulted in a
50% reduction in the mRNA expression level of survivin.

No statistically significant change was observed in the
survivin mRNA expression level of the CCD 841-CoN cell
line (Figure 6).
3.5. Protein levels of survivin, phosphorylated p53-Ser15,
and phosphorylated p53-Ser46 after CAPE treatment
The expression levels of survivin, and proteins p53-Ser15
and p53-Ser46 in the RKO and CCD 841-CoN cells were
examined via western blot analysis. Consistent with the
results of the qRT-PCR, the CAPE treatment decreased
the survivin protein level by approximately 5-fold in the
RKO cells. Moreover, the phosphorylated p53-Ser15 level
increased by 2.6 fold, while the p53-Ser46 protein level
increased by 3.5 fold in the RKO cells following CAPE
treatment. There was no significant change in the p53Ser15 and p53-Ser46 expression levels in the CCD 841CoN cells (Figure 7).
4. Discussion
Cancer is the second leading cause of death worldwide.
Aggressive progression and drug resistance have become
a challenge in the treatment of cancer. Recent studies on
cancer therapeutics have focused on targeting cellular
structures, such as survivin, which is involved in apoptotic
processes. Survivin is an IAP protein that is highly expressed
in most types of cancer (Altieri, 2003; Peery et al., 2017).
It is known that survivin is involved in tumorigenesis by
inhibiting caspases, such as caspase-3, -7, and -9, and
blocking p53-mediated apoptosis (Temrazet al., 2013;
Chenet al., 2016). Increased invasion and metastasis
have been shown to be related with an overexpression
of survivin in colorectal carcinoma (Chu et al., 2012).
Furthermore, survivin has been associated with reduced
survival rates of colorectal cancer patients (Kawasaki et
al., 1998). Different studies have shown that the expression
of survivin could be considered as a prognostic marker.

Figure 2. Survival rates of the RKO and CCD 841-CoN cells following treatment with effective doses of 5-FU, CAPE, or the combination
of CAPE +5-FU. Statistical significance between the untreated control group, CAPE treatment group, 5-FU treatment group, and CAPE
+5-FU treatment group was compared using one-way ANOVA analysis and the Tukey multiple comparisons test. ***P < 0.001.
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Figure 3. Fluorescence imaging of cell death in the RKO and CCD 841-CoN cells after CAPE treatment. Magnification
200×.

Furthermore, high expression levels of survivin in cancer
cells and its correlation with chemotherapy resistance
have suggested that it may be one of the key structures
to target for alternative treatment methods (Shenet al.,
2009). Therefore, the inhibition of survivin is thought to
be a promising therapeutic strategy in cancer treatment
(Peeryet al., 2017).
In alternative treatment-oriented cancer studies,
anticancer agents that selectively target cancer cells, rather
than healthy cells, were selected for use. CAPE is a wellknown component of propolis and has been widely used
in anticancer studies. Many reports have stated that CAPE
could induce apoptosis in different types of cancer cells.
Moreover, CAPE has been demonstrated to selectively kill
cancer cells (He et al. 2014; Murtaza et al. 2014). Therefore,
it was aimed herein to investigate the anticancer effects
of CAPE on RKO colorectal cancer cells and determine
changes in the survivin expression following CAPE
treatment.
Previous studies have shown that CAPE has the ability
to inhibit cell proliferation and tumor growth (Chen et
al., 2004; Kabala-Dzik et al., 2018). Therefore, in vitro
cell viability experiments were performed in this study
to analyze the effects of CAPE alone or in combination
with 5-FU. It was found that CAPE and 5-FU exhibited

cytotoxic effects on colorectal cancer cells in a dosedependent manner. However, the healthy colorectal cells
were not affected by the CAPE treatment, while 5-FU
significantly decreased the cell viability of the healthy cells
(Figures 1 and 2). Therefore, the selective cytotoxic effects
of CAPE on the cancer cells were determined, as previously
mentioned in the literature (Murtaza et al., 2014).
Consistently, the cancer cells started to exhibit apoptotic
morphology following the CAPE treatment, as observed
via the AO/EB staining (Figure 3). When the apoptotic
activity of CAPE was further analyzed, increased caspase-3
activity and apoptotic population was detected in the RKO
cells treated with CAPE (Figures 4 and 5). CAPE has been
shown to increase caspase-3 activity in different cell lines
and consequently induce apoptosis (Dziedzicet al., 2017;
Kabala-Dzik et al., 2018). In addition to these studies, the
data herein indicated that CAPE induced apoptosis by
increasing caspase-3 activity in the RKO colorectal cancer
cells, while low levels of caspase-3 activation occurred in
the CCD 841-CoN cells treated with CAPE.
Previous research has reported that CAPE treatment
alters the expression of different apoptotic genes in cancer
cells (Lin et al., 2012; Gherman et al., 2016). In this study,
it was detected that the CAPE treatment significantly
reduced the mRNA expression level of survivin when
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Figure 4. Flow cytometric analysis of the Annexin V/7AAD staining following CAPE
treatment in the RKO (A, B) and CCD 841-CoN (C, D) cells. Statistical significance between
the negative controls and treated groups was compared using the student t-test (E). ***P <
0.001.

compared to the untreated group of cells (Figure 6). It is
important to note that CAPE treatment could reduce the
level of mRNA expression in survivin, which is known to
be highly expressed in cancer cells and is associated with
resistance in treatment.
Following the detection of a change in the mRNA
level of survivin, the effects of the CAPE treatment on
the protein levels of survivin, p53-Ser15, and p53-Ser46
were observed. Post-translational modification of p53 is
known to contribute to the regulation of p53 stabilization
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and function. Specifically, the phosphorylation of p53 at
different residues determines its transcriptional activity,
thus causing specific types of responses to cellular
stress. Ser15 phosphorylation of p53 characterizes an
early cellular response to DNA damage and Ser46 is
an important phosphorylation site for the induction of
subsequent responses, particularly apoptosis (Kurihara
et al., 2007). In response to cellular stress following DNA
damage, phosphorylated p53 binds DNA and activates
apoptotic genes or suppresses antiapoptotic gene targets,

SARI et al. / Turk J Biol

Figure 5. Flow cytometric analysis of the caspase-3 activity following CAPE treatment
in the RKO (A, B) and CCD 841-CoN (C, D) cells. Statistical significance between
negative controls and treated groups was compared using the student t-test (E). *P <
0.05, ***P < 0.001.

including survivin. On the other hand, survivin has been
reported to regulate p53 expression. The overexpression
of survivin reduces p53-mediated apoptotic response and
this suggests that the inhibition of survivin may play an
important role in p53-mediated apoptosis (Mirza et al.,
2002; Chen et al., 2016; Li et al., 2018). In the current
study, a decrease in the protein expression of survivin was
detected following CAPE treatment. Conversely, the Ser46
and Ser15 phosphorylation of p53 increased (Figure 7).
These findings indicated that CAPE treatment can lead to
p53 activation by Ser15 phosphorylation, which in turn
may trigger the activation of apoptotic genes by Ser46

phosphorylation, thereby resulting in the suppression of
survivin expression.
Taken together, it was concluded that CAPE selectively
increased apoptotic activity through p53 activation and
survivin inhibition in colorectal cancer cells. Since this
apoptotic activity occurred selectively, without damaging
healthy cells, and survivin was the target of the CAPE
treatment, it is suggested that CAPE has the potential
to be an alternative anticancer agent. In this context,
understanding the mechanism of apoptosis, which was
induced by CAPE through p53 and survivin, might be
helpful to design alternative therapeutic strategies for the
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Figure 6. Relative mRNA expression levels of survivin in the RKO
and CCD 841-CoN cells following CAPE treatment. Statistical
significance between the negative controls and treated cell groups was
compared using the student t-test. *P < 0.05.

Figure 7. Effect of CAPE treatment on p53-Ser15, p53-Ser46, and survivin protein levels of the RKO
and CCD 841-CoN cells (A). Expressions of p53-Ser15, p53-Ser46, and survivin were normalized to
GAPDH. Fold changes were calculated relative to the untreated groups using the student t-test (B). *P
< 0.05.

treatment of colorectal cancer. To better understand this,
analyzing the changes in the levels of different proapoptotic
and antiapoptotic proteins, such as Bax, PUMA, NOXA,
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Bcl-2, and XIAP, following CAPE treatment will contribute
to the study. Furthermore, expanding this study by
using a known survivin inhibitor, such as sepantronium

SARI et al. / Turk J Biol
bromide (YM155), or by silencing the survivin and p53
expression via knockdown or knockout studies, will
provide substantial information about the effects of CAPE
treatment. Thereafter, in vivo studies using animal models
will help to describe the biological activities of CAPE.
Thus, further studies are required to evaluate the detailed
mechanisms of action.
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